Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

Homologous recombination (HR) is an important process that plays multiple crucial roles during meiosis, a type of cell cycle dedicated to sexual reproduction. During HR, homologous DNA molecules ...

Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer The efficiency of the Myriad Homologous ...

Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...

Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials Cancers with homologous recombination deficiency (HRD) can ...

Myriad Genetics received approval for a diagnostic test aimed at identifying advanced ovarian cancer patients eligible for treatment with Zejula from the Food and Drug Administration.

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...